Improved three-year disease-free survival in osteogenic sarcoma

Area of Science:

• Oncology
• Pediatric Oncology
• Surgical Oncology

Background:

• Osteosarcoma is a rare bone cancer primarily affecting children and young adults.
• Treatment historically relied on surgery, with limited success in preventing metastasis and improving survival.
• The need for effective adjuvant therapies to improve outcomes in osteosarcoma was recognized.

Purpose of the Study:

• To evaluate the efficacy of adjunctive chemotherapy in improving survival and disease-free survival for osteosarcoma patients.
• To compare outcomes in patients treated with and without adjuvant chemotherapy.
• To assess the impact of chemotherapy on the onset of metastatic disease.

Main Methods:

• A retrospective study comparing two groups of osteosarcoma patients treated between 1952 and 1977.
• Historical group (n=19): treated before 1973, without adjuvant chemotherapy.
• Chemotherapy group (n=22): treated after 1972, with adjuvant chemotherapy (methotrexate and adriamycin).

Main Results:

• The chemotherapy group demonstrated a significant increase in overall survival (p=0.03) and disease-free survival (p=0.02) compared to the historical group.
• For localized disease, three-year survival rates were 41% (historical) vs. 78% (chemotherapy), and three-year disease-free survival was 18% (historical) vs. 67% (chemotherapy).
• Adjunctive chemotherapy rarely delayed the onset of pulmonary metastases.

Conclusions:

• Adjunctive chemotherapy, primarily high-dose methotrexate and adriamycin, significantly improves both overall and disease-free survival in osteosarcoma patients.
• The observed benefits were independent of patient age, sex, metastatic status, histopathology, tumor location, or surgical approach.
• This study supports the use of adjuvant chemotherapy as a critical component in the management of osteosarcoma.